CLINICAL TRIALS PROFILE FOR ENSIFENTRINE
✉ Email this page to a colleague
All Clinical Trials for ensifentrine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04527471 ↗ | Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 | Active, not recruiting | Verona Pharma Inc | Phase 2 | 2020-09-04 | This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients hospitalized due to COVID-19 infection. |
| NCT04535986 ↗ | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | Recruiting | Iqvia Pty Ltd | Phase 3 | 2020-09-29 | The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). |
| NCT04535986 ↗ | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | Recruiting | Verona Pharma plc | Phase 3 | 2020-09-29 | The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). |
| NCT04542057 ↗ | A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | Recruiting | Iqvia Pty Ltd | Phase 3 | 2020-09-22 | The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). |
| NCT04542057 ↗ | A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | Recruiting | Verona Pharma plc | Phase 3 | 2020-09-22 | The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). |
| NCT05270525 ↗ | Effect of Ensifentrine on Sputum Markers of Inflammation in COPD | Not yet recruiting | University of Alabama at Birmingham | Phase 2 | 2022-04-01 | This is a single center, randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up to 24 weeks participation. |
| NCT05270525 ↗ | Effect of Ensifentrine on Sputum Markers of Inflammation in COPD | Not yet recruiting | Verona Pharma plc | Phase 2 | 2022-04-01 | This is a single center, randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up to 24 weeks participation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ensifentrine
Condition Name
Clinical Trial Locations for ensifentrine
Trials by Country
Clinical Trial Progress for ensifentrine
Clinical Trial Phase
Clinical Trial Sponsors for ensifentrine
Sponsor Name
